James M Sullivan Net Worth

The estimated Net Worth of James M Sullivan is at least $2.13 Millón dollars as of 6 March 2018. James Sullivan owns over 15,658 units of SeaSpine Corp stock worth over $717,999 and over the last 21 years James sold SPNE stock worth over $1,415,700.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

James Sullivan SPNE stock SEC Form 4 insiders trading

James has made over 18 trades of the SeaSpine Corp stock since 2003, according to the Form 4 filled with the SEC. Most recently James exercised 15,658 units of SPNE stock worth $282,783 on 6 March 2018.

The largest trade James's ever made was exercising 176,130 units of SeaSpine Corp stock on 13 February 2006 worth over $4,334,559. On average, James trades about 12,259 units every 84 days since 2003. As of 6 March 2018 James still owns at least 75,262 units of SeaSpine Corp stock.

You can see the complete history of James Sullivan stock trades at the bottom of the page.

Insiders trading at SeaSpine Corp

Over the last 9 years, insiders at SeaSpine Corp have traded over $2,659,931 worth of SeaSpine Corp stock and bought 297,805 units worth $3,591,897 . The most active insiders traders include Stuart Essig, Richard E Caruso y Keith Valentine. On average, SeaSpine Corp executives and independent directors trade stock every 39 days with the average trade being worth of $151,762. The most recent stock trade was executed by John J. Winge on 1 January 2023, trading 4,868 units of SPNE stock currently worth $46,441.

What does SeaSpine Corp do?

SeaSpine (www.seaspine.com) is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implants solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine's orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine's spinal implants portfolio consists of an extensive line of products to facilitate spinal fusion in degenerative, minimally invasive surgery (MIS), and complex spinal deformity procedures. Expertise in both orthobiologic sciences and spinal implants product development allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in approximately 30 countries worldwide.

Complete history of James Sullivan stock trades at Integra Lifesciences Corp, Marriott International y SeaSpine Corp

SeaSpine Corp executives and stock owners

SeaSpine Corp executives and other stock owners filed with the SEC include:

• Keith Valentine,
  President, Chief Executive Officer, Director
• Keith C. Valentine,
  Pres, CEO & Director
• John Bostjancic,
  Chief Financial Officer, Senior Vice President, Treasurer
• Tyler Lipschultz,
  Senior Vice President, Orthobiologics and Business Development
• Patrick Keran,
  Vice President, General Counsel, Secretary
• John Winge,
  Vice President of Sales
• John J. Bostjancic,
  Sr. VP, CFO & Treasurer
• Patrick L. Keran,
  Sr. VP, Gen. Counsel & Sec.
• Dr. Beau Standish P.Eng., Ph.D.,
  Pres of Enabling Technologies
• Kimberly Commins-Tzoumakas,
  Independent Director
• Renee Gaeta,
  Independent Director
• Kirtley Stephenson,
  Independent Non-Executive Chairman of the Board
• Stuart Essig,
  Lead Independent Director
• Michael Fekete,
  Independent Director
• Keith Bradley,
  Independent Director
• John Henneman,
  Independent Director
• Dennis Cirino,
  Senior Vice President, Global Spinal Systems
• Hollis Winkler,
  Sr. VP of HR
• Patrick L. Keran J.D.,
  Sr. VP, Gen. Counsel & Sec.
• Dr. Frank Vizesi,
  Chief Scientific Officer
• Shaeffer Bannigan,
  Sr. Director of Product Devel.
• Paul Benny,
  VP, Corp. Controller, Assistant Treasurer & Assistant Sec.
• Dr. Beau Standish Ph.D.,
  Pres of Enabling Technologies
• Dennis L. Cirino,
  Sr. VP of Global Spinal Systems
• Tyler P. Lipschultz,
  Sr. VP of Orthobiologics & Bus. Devel.
• John J. Winge,
  VP of Sales
• Carrie Mendivil,
  Head of Investor Relations
• James M Sullivan,
  Director
• Cheryl R Blanchard,
  Director
• Brian D. Baker,
  VP, Global Operations
• Richard E Caruso,
  10% owner
• Shweta Maniar,
  Director
• Life Sciences Corp Integra ...,
  
• Beau Standish,
  President, Enabling Tech
• Angela Steinway,
  Director